| Control | MMA | SA | |
| Subjects n | 17 | 35 | 19 |
| Age yrs | 49 (33–70) | 49 (29–68) | 53 (33–71) |
| Males/females n | 6/11 | 13/22 | 5/14 |
| Asthma duration yrs | 34 (5–63) | 37 (13–65) | |
| FEV1 % pred | 92.7±9.8 | 78.7±8.1* | 65.3±17.5+,§ |
| Atopy n | 19 | 7 | |
| LABA n | 26 | 19 | |
| ICS μg# | 35 (680±420) | 19 (1950±570) | |
| CS mg p.o.¶ | 8 (8.4±2.8) |
Data are presented as mean±sd or mean (range), unless otherwise indicated. MMA: mild-to-moderate asthma; SA: severe asthma; FEV1: forced expiratory volume in 1 s; % pred: % predicted; LABA: long-acting β2-agonist; ICS: inhaled corticosteroid; CS: corticosteroid. #: beclometasone or beclometasone equivalent dose; ¶: prednisolone or prednisolone equivalent dose. *: p<0.05; +: p<0.001 versus healthy controls; §: p<0.05 versus MMA.